We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

25 hedge funds and large institutions have $39.9M invested in Xenon Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

0% more funds holding

Funds holding: 25 → 25 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

14% less capital invested

Capital invested by funds: $46.5M → $39.9M (-$6.56M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
25
Holders Change
–
Holders Change %
0%
% of All Funds
0.67%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
1
Increased
7
Reduced
6
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BI
BVF Inc
California
+$4.67M
2
OM
Opaleye Management
Massachusetts
+$719K
3
DCM
DAFNA Capital Management
California
+$686K
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$296K
5
WMSA
Weiss Multi-Strategy Advisers
New York
+$43.1K

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$7.32M
2
GCP
GSA Capital Partners
United Kingdom
-$175K
3
VAM
Visium Asset Management
New York
-$144K
4
Renaissance Technologies
Renaissance Technologies
New York
-$38.1K
5
UBS Group
UBS Group
Switzerland
-$10.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$12.4M +$4.67M +650,000 +58%
Capital World Investors
2
Capital World Investors
California
$7.2M – – –
Royal Bank of Canada
3
Royal Bank of Canada
Ontario, Canada
$3.27M -$2.06K -286 -0.1%
IPC
4
Invesco Private Capital
New York
$3.05M – – –
VAM
5
Visium Asset Management
New York
$2.94M -$144K -20,000 -5%
OM
6
Opaleye Management
Massachusetts
$2.8M +$719K +100,000 +33%
Point72 Asset Management
7
Point72 Asset Management
Connecticut
$2.51M +$296K +41,146 +13%
PA
8
Perceptive Advisors
New York
$1.44M – – –
DCM
9
DAFNA Capital Management
California
$1.35M +$686K +95,465 +98%
NHAS
10
Novo Holdings A/S
Denmark
$892K – – –
JC
11
JBF Capital
Colorado
$480K – – –
State of New Jersey Common Pension Fund D
12
State of New Jersey Common Pension Fund D
New Jersey
$454K – – –
WMSA
13
Weiss Multi-Strategy Advisers
New York
$356K +$43.1K +6,000 +13%
Renaissance Technologies
14
Renaissance Technologies
New York
$236K -$38.1K -5,305 -14%
LWIC
15
Leith Wheeler Investment Counsel
British Columbia, Canada
$146K – – –
NSEDCP
16
NJ State Employees Deferred Compensation Plan
New Jersey
$143K – – –
GCP
17
GSA Capital Partners
United Kingdom
$94K -$175K -24,407 -65%
Deutsche Bank
18
Deutsche Bank
Germany
$53K -$223 -31 -0.4%
Bank of Montreal
19
Bank of Montreal
Ontario, Canada
$50K – – –
Wells Fargo
20
Wells Fargo
California
$34K +$2.59K +361 +8%
TRCT
21
Tower Research Capital (TRC)
New York
$17K +$7.73K +1,075 +85%
UBS Group
22
UBS Group
Switzerland
$8K -$10.9K -1,523 -58%
Morgan Stanley
23
Morgan Stanley
New York
$6K – – –
Citigroup
24
Citigroup
New York
$5K – – –
Walleye Trading
25
Walleye Trading
New York
$2K +$2.16K +300 New
1
2

XENE Hedge Fund Activity: Q1 2016 in Review

25 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2016, worth a combined $39.9M — down 14% from $46.5M a quarter earlier.

Fund positioning in XENE was balanced in Q1 2016: 1 fund opened new positions, 1 closed out, 7 added to existing stakes and 6 trimmed.

The largest buyer was BVF Inc, adding an estimated $4.67M. The largest seller was Fidelity Investments, exiting entirely with an estimated $7.32M sold.

  • 25 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2016, unchanged from Q4 2015.
  • Funds reported $39.9M of Xenon Pharmaceuticals stock for Q1 2016, down 14% quarter-over-quarter.
  • 1 fund opened new Xenon Pharmaceuticals positions in Q1 2016 and 1 closed out, a net change of 0 holders.
  • The largest Xenon Pharmaceuticals buyer in Q1 2016 was BVF Inc, an estimated $4.67M added.
  • The largest Xenon Pharmaceuticals seller in Q1 2016 was Fidelity Investments, an estimated $7.32M sold.

Based on aggregated 13F filings for Q1 2016.